Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-06-26
2007-06-26
Fay, Zohreh (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S912000
Reexamination Certificate
active
10824013
ABSTRACT:
Fused pyridazine derivatives are useful for treating dry eye disorders and other disorders requiring the wetting of the eye.
REFERENCES:
patent: 4131651 (1978-12-01), Shah et al.
patent: 4370325 (1983-01-01), Packman
patent: 4409205 (1983-10-01), Shively
patent: 4744980 (1988-05-01), Holly
patent: 4818537 (1989-04-01), Guo
patent: 4883658 (1989-11-01), Holly
patent: 4914088 (1990-04-01), Glonek et al.
patent: 4966773 (1990-10-01), Gressel et al.
patent: 5041434 (1991-08-01), Lubkin
patent: 5075104 (1991-12-01), Gressel et al.
patent: 5174988 (1992-12-01), Mautone et al.
patent: 5278151 (1994-01-01), Korb et al.
patent: 5290572 (1994-03-01), MacKeen
patent: 5294607 (1994-03-01), Glonek et al.
patent: 5371108 (1994-12-01), Korb et al.
patent: 5578586 (1996-11-01), Glonek et al.
patent: 5696166 (1997-12-01), Yanni et al.
patent: 5800807 (1998-09-01), Hu et al.
patent: 5958912 (1999-09-01), Sullivan
patent: 6153607 (2000-11-01), Pflugfelder et al.
patent: 6248740 (2001-06-01), Kawano et al.
patent: 2004/0058875 (2004-03-01), Gamache
patent: 1 123 936 (2001-08-01), None
patent: 1 243 271 (2002-09-01), None
patent: 1 426 050 (2004-06-01), None
patent: WO 00/03705 (2000-01-01), None
patent: WO 02/48135 (2002-06-01), None
patent: WO 03/053452 (2003-07-01), None
Fukuda et al., “Inhibition of Allergic Dermal Inflammation by the Novel Imidazopyridazine Derivative TAK-427 in a Guinea Pig Experimental Model of Eczema,”J. of Pharmacology and Exerimental Therapeutics, vol. 303(3); pp. 1283-1290 (2002).
Lemp et al., “Report of the National Eye Institute/Industry Workship on Clinical Trials in Dry Eyes,”CLAO Journal, vol. 21(4), pp. 221-231 (1995).
McCulley et al., “Tear Film Structure and Dry Eye,”Contactologia, vol. 20, pp. 145-149 (1998).
Marsh et al., “Topical Nonpreserved Methylprednisolone Therapy for Keratoconjunctivitis Sicca in Sjogren Syndrome,”Ophthalmology, vol. 106(4), pp. 811-816 (1999).
Shine et al., “Keratoconjunctivitis Sicca Associated with Meibomian Secretion Polar Lipid Abnormality,”Arch. Ophthalmol., vol. 116, pp. 849-852 (1998).
Tauber et al., “A Dose-Ranging Clinical Trial to Assess the Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients with Keratoconjunctivitis Sicca,” Lacrimal Gland, Tear Film and Dry Eye Syndromes 2, edited by Sullivan et al., Plenum Press, New York, pp. 969-972 (1998).
Li et al., “Hyperosmolarity Stimulates Producito of MMP-9, IL-kbeta and TNF-alpha by Human Corneal Epithelial Cells via a c-June NH2-terminal Kinase Pathway,” Annual Meeting of the Association for Research in Vision and Ophthalmology; Fort Lauderdale, FL, May 5-10, 2002, Abstract No. 1981.
Pflugfelder et al., “Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca,”Current Eye Research, vol. 19 (3), pp. 201-211 (1999).
Pflugfelder, “Antiinflammatory Therpay for Dry Eye,”American J. of Ophthalmology, vol. 137(2), pp. 337-342 (2004).
Hellberg Mark R.
Sharif Najam A.
Alcon Inc.
Fay Zohreh
Ryan Patrick M.
LandOfFree
Methods of treating dry eye disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating dry eye disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating dry eye disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3850064